Guardant Health (MEX:GH) EBIT: MXN-7,856 Mil (TTM As of Mar. 2026)


MEX:GH Guardant Health Inc MEX:GH
67 GF Score
Price MXN2,080.00
GF Value MXN879.06
! 4 Warning Signs
View Full Analysis

What is Guardant Health EBIT?

Guardant Health MEX:GH 67 EBIT is MXN-7,856 Mil as of Mar. 2026. GuruFocus rates MEX:GH with a GF Score™ of 67/100 and a GF Value™ of MXN879.06. The stock has 4 warning signs investors should review.

Guardant Health's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was MXN-1,990 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was MXN-7,856 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Guardant Health's annualized ROC % for the quarter that ended in Mar. 2026 was -66.52%. Guardant Health's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -145.15%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Guardant Health's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -2.28%.


Guardant Health  (MEX:GH) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Guardant Health's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-8753.072 * ( 1 - 0% )/( (13426.689 + 12891.83)/ 2 )
=-8753.072/13159.2595
=-66.52 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=36257.34 - 1884.333 - ( 21635.613 - max(0, 5450.866 - 26397.184+21635.613))
=13426.689

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=34537.868 - 2254.394 - ( 19885.74 - max(0, 5268.163 - 24659.807+19885.74))
=12891.83

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Guardant Health's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-7960.068/( ( (5487.489 + max(-284.545, 0)) + (5480.877 + max(-100.442, 0)) )/ 2 )
=-7960.068/( ( 5487.489 + 5480.877 )/ 2 )
=-7960.068/5484.183
=-145.15 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(2388.438 + 1546.257 + 733.246) - (1884.333 + 913.843 + 2154.31)
=-284.545

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(2365.962 + 1512.06 + 784.242) - (2254.394 + 861.458 + 1646.854)
=-100.442

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Guardant Health's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-7856.458/344752.065
=-2.28 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Guardant Health EBIT Related Terms


Guardant Health EBIT Historical Data

* Premium members only.

The historical data trend for Guardant Health's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Guardant Health EBIT Chart

Guardant Health Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7,834.15 -12,689.40 -8,082.90 -9,020.26 -7,447.93

Guardant Health Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,924.67 -1,861.79 -1,681.17 -2,323.47 -1,990.02

MEX:GH vs LH, DGX, MEDP: EBIT Comparison

For the Diagnostics & Research subindustry, Guardant Health's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Guardant Health EV-to-EBIT vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Guardant Health's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Guardant Health's EV-to-EBIT falls into.


MEX:GH
67GF Score
Guardant Health Inc MEX:GH
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Guardant Health EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-7,856 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of MXN-7,856 Mil mean?
Guardant Health (MEX:GH) has a EBIT of MXN-7,856 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Guardant Health.
Is Guardant Health's EBIT too high?
Guardant Health's current EBIT is MXN-7,856 Mil. Overall, Guardant Health has a GF Score™ of 67/100, reflecting its overall financial health beyond just this single metric.
How does Guardant Health's EBIT compare to LH and DGX?
Guardant Health's EBIT of MXN-7,856 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Diagnostics & Research company?
A good EBIT depends on the Medical Diagnostics & Research industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Guardant Health. Guardant Health's current EBIT is MXN-7,856 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guardant Health stock overvalued right now?
Guardant Health (MEX:GH) has a current EBIT of MXN-7,856 Mil. The stock's GF Value™ is MXN879.06, compared to a current price of MXN2,080.00 — trading 136.6% above its estimated fair value. The current EBIT is MXN-7,856 Mil. Guardant Health's overall GF Score™ is 67/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Guardant Health (MEX:GH), the current EBIT is MXN-7,856 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Guardant Health (MEX:GH) Overvalued in 2026?

Based on GuruFocus' analysis, Guardant Health stock appears to be overvalued. The current stock price of MXN2,080.00 is trading 136.6% above its estimated GF Value™ of MXN879.06.

Key valuation signals for MEX:GH:

  • EBIT: MXN-7,856 Mil
  • GF Value™: MXN879.06 vs. price of MXN2,080.00 (136.6% above fair value)
  • GF Score™: 67/100 with 4 warning signs

No single metric tells the full story. See the MEX:GH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Guardant Health Business Description

Other Exchanges GH:USA1GH:Italy5GH:Germany
Address 3100 Hanover Street, Palo Alto, CA, USA, 94304
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
67GF Score

Get the complete analysis for MEX:GH

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN2,080.00
Price
MXN879.06
GF Value